Adam Zamecnik

Delegates from European institutions and industry representatives unpacked the many challenges of improved access to critical medicines on the continent in a session at this year's European Health Forum.

Years after the patent application's initial filing in 2007, the Indian Patent Office has dismissed ViiV's claims in response to multiple opposition filings launched against the pharma player.

Only a month after filing their second biosimilar application with Japanese regulators, Alvotech and Fuji have submitted a further one for an undisclosed biosimilar as part of their local partnership.

After sharing multiple updates to the regulatory status of its ketamine formulation, PharmaTher received a complete response letter from the FDA, which required minor information and clarifications from the company.

Only days after its initial announcement, Hypera Pharma has refused EMS' proposed merger on grounds of undervaluation and different strategic priorities.

Attended by several government delegates, the opening of the multi-million dollar antibiotic plant highlighted the Indian government's ongoing policy to bolster domestic pharmaceutical manufacturing.

After a “solid start to the year”, Organon has delivered on analyst expectations with its third quarter results, despite ongoing questions surrounding future growth and market penetration of key compounds. Meanwhile, the firm's filing for a biosimilar rival to Prolia/Xgeva has been accepted by the FDA.

After past challenges caused by reimbursement drug price cuts imposed by the Japanese government, Chemiphar has managed to keep its operating profits in the black in the second quarter of its 2024 financial year.

Reflecting the company's acquisition of Alimera Sciences, ANI Pharmaceuticals has shared the first results that included new assets as it pushes to a more diversified business strategy.

Krka has maintained strong growth in the past nine months despite ongoing questions surrounding its significant presence in Russia and foreign currency risks linked to the rouble.